Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 15/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 15/20 | 0.41 |
| ▸ | WNT1 | P04628 | 3/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5946846 | 0.75 | HTR2A (0.50) | RHOANCF1 | |
| SCHEMBL7121980 | 0.74 | IDO1 (0.46) | IDO1HPGDSGSK3BDYRK1AWNT1 | |
| SCHEMBL7977724 | 0.74 | RHOA (0.44) | RHOAGSK3BDYRK1ANCF1 | |
| SCHEMBL4515256 | 0.72 | IDO1 (0.57) | IDO1HPGDSGSK3BDYRK1AWNT1 | |
| SCHEMBL29809180 | 0.70 | RAB9A (0.48) | IDO1HPGDS | |
| SCHEMBL21128683 | 0.70 | IDO1 (0.68) | IDO1HPGDSGSK3BDYRK1A | |
| SCHEMBL29833517 | 0.69 | NCF1 (0.61) | RHOANCF1 | |
| SCHEMBL396525 | 0.69 | NCF1 (0.61) | RHOANCF1 | |
| SCHEMBL1701970 | 0.69 | NPC1 (0.61) | RHOAGSK3BNCF1 | |
| SCHEMBL3951916 | 0.69 | IGF1R (0.55) | RHOANCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | IDO1 1301/4885RHOA 2467/4885HPGDS 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.